A Next-Act in Life Saving Treatments
Dr. Susan Dillon is the co-founder of Aro Biotherapeutics and has led research teams for brands such as Johnson & Johnson to develop innovative medicines for autoimmune diseases. ?
Dr. Dillon is now in the second act of her career and she is not slowing down one bit. Her new project is the development of Centyrin - a new drug that addresses unmet medical needs.
In an interview with Ashton Tweed, Dr. Dillon discusses the questions she asks all prospective team members and why Centyrins could be the next big development for medicines that directly modulate the genes involved in causing the disease:
“The complex projects we took on were like sending a rocket ship to the moon—it was that magnitude,” Dr. Dillon recalls.
You can find her story here.